S-ICD Shows Virtues, Limits in 'Real World' Postmarket Study
The subcutaneous-lead ICD's strengths and weaknesses in a registry study mirrored its performance in earlier trials, 11 years after its US approval.
Source: medscape.com
Stay updated with breaking news from Jonathans Steinberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The subcutaneous-lead ICD's strengths and weaknesses in a registry study mirrored its performance in earlier trials, 11 years after its US approval.